Trial · NCT03106623
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy (Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours) | Baseline and Week 4 | |
| Secondary | Safety (adverse event, vital signs, 12-lead electrocardiography, residual urine volume, clinical laboratory test) | Up to Week 4 | |
| Secondary | Pharmacokinetics (plasma concentration at one point on each visit) | Week 2 and 4 | |
| Secondary | Efficacy (Change From Baseline to Week 2 in Mean Number of Micturitions Per 24 Hours) | Baseline and Week 2 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Micturitions Per 24 Hours) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Incontinence Episodes Per 24 Hours) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Urgency Incontinence Episodes Per 24 Hours) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Urgency Episodes Per 24 Hours) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Nocturia Episodes Per 24 Hours) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Percentage of Participants With ˂8 times of Micturitions Per 24 Hours at Week 2 and 4) | Week 2 and 4 | |
| Secondary | Efficacy (Percentage of Participants With Zero Incontinence Episodes at Week 2 and 4 | Week 2 and 4 | |
| Secondary | Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Volume Voided Per Micturition) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change From Baseline to Week 2 and 4 in Overactive Bladder Symptom Score (OABSS) ) | Baseline, Week 2 and 4 | |
| Secondary | Efficacy (Change From Baseline to Week 4 in Health-related Quality of Life) | Baseline and Week 4 | |
| Secondary | Efficacy (Patient Global Impression at Week 4) | Week 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03106623/registered